These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15045839)

  • 1. [Candesartan reduces the risk of mortality and recurrence of chronic heart failure. Important results from the CHARM study].
    Persson H; Swedberg K
    Lakartidningen; 2004 Feb; 101(9):764-6. PubMed ID: 15045839
    [No Abstract]   [Full Text] [Related]  

  • 2. [New treatment of heart failure. Angiotensin II receptor blockaders show promising results in an extensive study].
    Dahlström U
    Lakartidningen; 2004 Feb; 101(9):742-3. PubMed ID: 15045837
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H; Komuro I
    Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.
    Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753
    [No Abstract]   [Full Text] [Related]  

  • 6. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS
    J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers in heart failure.
    Stergren J; McMurray JJ
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):171-5. PubMed ID: 14608522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candesartan and heart failure: the allure of CHARM.
    White HD
    Lancet; 2003 Sep; 362(9386):754-5. PubMed ID: 13678864
    [No Abstract]   [Full Text] [Related]  

  • 9. CHARM shows improvement in NYHA functional class with candesartan.
    Cardiovasc J S Afr; 2004; 15(2):96-7. PubMed ID: 15148548
    [No Abstract]   [Full Text] [Related]  

  • 10. [Benefits of candesartan in the treatment of symptomatic heart failure--CHARM programme].
    Umemoto S; Matsuzaki M
    Nihon Rinsho; 2004 Jan; 62(1):211-8. PubMed ID: 14737855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CHARM programme.
    Penston J
    Lancet; 2003 Nov; 362(9396):1678; author reply 1678-9. PubMed ID: 14630459
    [No Abstract]   [Full Text] [Related]  

  • 12. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.
    Bhakta S; Dunlap ME
    Cleve Clin J Med; 2004 Aug; 71(8):665-73. PubMed ID: 15449762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of angiotensin II receptor antagonist on heart failure].
    Matsumori A
    Nihon Rinsho; 2004 Jan; 62(1):203-10. PubMed ID: 14737854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    McMurray JJ; Andersson FL; Stewart S; Svensson K; Solal AC; Dietz R; Vanhaecke J; van Veldhuisen DJ; Ostergren J; Granger CB; Yusuf S; Pfeffer MA; Swedberg K
    Eur Heart J; 2006 Jun; 27(12):1447-58. PubMed ID: 16754631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CHARM programme.
    Pechlaner C
    Lancet; 2003 Nov; 362(9396):1675-6; author reply 1678-9. PubMed ID: 14630453
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.
    McKelvie RS
    Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):9-16. PubMed ID: 19105762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.